PMS Registry
Company Name
Daiichi Sankyo Taiwan
Protocol Number
Title of Study
Non-interventional study on edoxaban treatment in routine clinical practice for patients with non valvular atrial fibrillation in Korea and Taiwan
Primary Objective
The primary objective of this study is to collect and evaluate real-world safety data on bleeding events including intracranial haemorrhage, adverse events such as liver adverse events, cardiovascular (CV) and all-cause mortality in NVAF patients treated with edoxaban up to 2 years with regard to onset (relative to treatment with edoxaban) of the event, duration, severity and outcome.
Number of Sites
Period of Study
From:04/06/2017 to:04/05/2021
Number of Patients
IRB Approval Date
Dec. 19, 2016
Publication Plan / Date